The result showing that SGLT2 inhibitors had a similar risk of hypoglycemia as a placebo [risk ratio 1.16 (95% CI 0.93–1.45), I2 = 16%] was consistent with previous findings36; however, their data differed from the present study, which partially included patients with type 1 DM. Here, SLC5A2 is linked to Hypoglycemia.